I have more than 20 years of experience working in biotechnology, with a focus on Clinical Development and Quality, where I have been dedicated to helping to bring important therapies to patients with limited or no treatment options. In my role at Dynacure, I design clinical trials to demonstrate if a potential treatment can safely and effectively address the needs of a patient community, and I work to ensure that such studies are aligned to the feedback and insight we receive from patients, physicians, and regulatory authorities.
I oversee the design and execution of the clinical studies for our lead program DYN-101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein (DNM2) for the treatment of Myotubular and Centronuclear Myopathies (CNM).
Last year, we began to dose the first patients through our Unite-CNM clinical study – a multicenter, ascending dose study Phase 1/2 clinical trial to evaluate DYN101. The trial is expected to enroll approximately 18 patients aged 16 years or older with X-linked myotubular myopathy (XLCNM) or autosomal dominant CNM (ADCNM). I am excited that as an organization we have entered this phase of development, with the potential to help patients who are desperately in need of treatment options. I am also excited about the potential of this investigational therapy to make a difference, and to learn from each heroic patient’s experience.
Always seek deeper understanding before searching for solutions.
In my work this means looking for the drivers behind what people say or do, asking why a regulation was created, or what the patients really need. Only with this level of understanding you can be truly creative and find solutions that ensure progress in your clinical program despite the inevitable challenges. Seeking to understand first, will give you the opportunity to influence with impact in any area of your life.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookies that may not be particularly necessary for the website to function and are used specifically by Dynacure, as data controller, to collect user personal data via analytics are termed as non-necessary cookies. It is mandatory to procure your user consent prior to running these cookies on our website. After consenting, you may withdraw your consent at any time via the cookies page. Refusing these cookies will have no impact on your individual use of the website but will impact our ability to improve it for the benefit of future users.